micro-community-banner
 
  • Saved

3mo
Psych Congress 2025: Moving beyond symptom control toward holistic psychiatric care

At Psych Congress 2025, thought leaders emphasized a shift in psychiatric care from symptom control toward enhancing patient functioning and quality of life. Dr. Julie Carbray, Clinical Professor of Psychiatry and Nursing at the University of Illinois Chicago, discussed incorporating sleep science and digital therapeutics into treatment strategies for depression and ADHD to support whole-person care. Dr. Christoph Correll, Professor of Psychiatry and Molecular Medicine at Zucker School of Medicine, presented data on long-acting subcutaneous therapy for schizophrenia, emphasizing its sustained clinical impact. Collectively, these insights highlight psychiatry’s evolving commitment to evidence-based, patient-centered approaches.

  • Saved

3mo
Therapeutic potential of IFIT2 in human diseases - PubMed

Therapeutic potential of IFIT2 in human diseases - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41046825/

The interferon-induced protein with tetratricopeptide repeats 2 (IFIT2) is a crucial member of the interferon-stimulated gene (ISG) family, widely acknowledged for its antiviral activity. IFIT2 functions primarily through AU-rich RNA...

This review examines IFIT2’s roles in antiviral defense, cancer, autoimmunity, neurological disorders, and metabolic diseases, proposing its translational promise as a biomarker and therapeutic target in multiple pathologies including MS.

  • Saved

4mo
Determinants of clinical trial failure in multiple sclerosis: insights from ClinicalTrials.gov - PubMed

Determinants of clinical trial failure in multiple sclerosis: insights from ClinicalTrials.gov - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41001525/

One out of four MS clinical trials fails. Increasing the number of study sites and improving recruitment strategies could enhance their success rates.

Analysis of 282 MS clinical trials found 25% failed, mainly due to low recruitment, business decisions, and logistics. Trials with larger sites and safety endpoints showed higher success, emphasizing recruitment improvement.

  • Saved

4mo
Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis - PubMed

Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40967951/

The 2024 McDonald diagnostic criteria for Multiple Sclerosis (MS) introduce kappa free light chains (κ-FLC) detection in cerebrospinal fluid (CSF) which can be used interchangeably with oligoclonal IgG bands (OCB)...

The 2024 McDonald criteria integrate kappa free light chain detection in cerebrospinal fluid as an alternative to oligoclonal bands, enhancing diagnostic accuracy and offering prognostic insights for both pediatric and adult MS.

  • Saved

4mo
Association of Spinal Cord Radiomic Features and Disability in Multiple Sclerosis - PubMed

Association of Spinal Cord Radiomic Features and Disability in Multiple Sclerosis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40947502/

Radiomics identified pathological changes in pwMS in varying stages of the disease course that are undetectable by conventional spinal cord MRI. Radiomics may increase the yield of spinal cord MRI...

Radiomic analysis of spinal cord MRI in multiple sclerosis patients detected pathological changes undetectable by conventional imaging, distinguishing subgroups and correlating with disability more strongly than traditional measures, suggesting biomarker potential.